학술논문
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19
Document Type
article
Author
Börger, Verena; Weiss, Daniel J; Anderson, Johnathon D; Borràs, Francesc E; Bussolati, Benedetta; Carter, David RF; Dominici, Massimo; Falcón-Pérez, Juan M; Gimona, Mario; Hill, Andrew F; Hoffman, Andrew M; de Kleijn, Dominique; Levine, Bruce L; Lim, Rebecca; Lötvall, Jan; Mitsialis, S Alex; Monguió-Tortajada, Marta; Muraca, Maurizio; Nieuwland, Rienk; Nowocin, Anna; O'Driscoll, Lorraine; Ortiz, Luis A; Phinney, Donald G; Reischl, Ilona; Rohde, Eva; Sanzenbacher, Ralf; Théry, Clotilde; Toh, Wei Seong; Witwer, Kenneth W; Lim, Sai Kiang; Giebel, Bernd
Source
Cytotherapy. 22(9)
Subject
Language
Abstract
StatementThe International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.